ATE135573T1 - Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten - Google Patents

Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten

Info

Publication number
ATE135573T1
ATE135573T1 AT92201037T AT92201037T ATE135573T1 AT E135573 T1 ATE135573 T1 AT E135573T1 AT 92201037 T AT92201037 T AT 92201037T AT 92201037 T AT92201037 T AT 92201037T AT E135573 T1 ATE135573 T1 AT E135573T1
Authority
AT
Austria
Prior art keywords
treatment
autoimmune diseases
methoxyalcaneous
indazole
acid
Prior art date
Application number
AT92201037T
Other languages
English (en)
Inventor
Bruno Silvestrini
Original Assignee
Angelini Ricerche Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angelini Ricerche Spa filed Critical Angelini Ricerche Spa
Application granted granted Critical
Publication of ATE135573T1 publication Critical patent/ATE135573T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92201037T 1991-04-22 1992-04-11 Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten ATE135573T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911101A IT1253703B (it) 1991-04-22 1991-04-22 Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie

Publications (1)

Publication Number Publication Date
ATE135573T1 true ATE135573T1 (de) 1996-04-15

Family

ID=11359721

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92201037T ATE135573T1 (de) 1991-04-22 1992-04-11 Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten

Country Status (16)

Country Link
US (1) US5278183A (de)
EP (1) EP0510748B1 (de)
JP (1) JP3056879B2 (de)
KR (1) KR100210199B1 (de)
AT (1) ATE135573T1 (de)
AU (1) AU657524B2 (de)
BG (1) BG61366B2 (de)
CA (1) CA2066304C (de)
CZ (1) CZ280613B6 (de)
DE (1) DE69209128T2 (de)
DK (1) DK0510748T3 (de)
IL (1) IL101660A (de)
IT (1) IT1253703B (de)
NZ (1) NZ242392A (de)
SK (1) SK278546B6 (de)
ZA (1) ZA922740B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723315B1 (fr) * 1994-08-02 1996-10-25 Cird Galderma Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
WO2003035005A2 (en) * 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
DK2254869T3 (en) 2008-03-07 2017-09-04 Acraf 1-BENZYL-3-HYDROXYMETHYL INDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40
MX2010009625A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
EA018185B1 (ru) 2008-03-07 2013-06-28 Ацьенде Кимике Рьюните Анджелини Франческо A.К.P.A.Ф. С.П.А. Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 или cx3cr1
BR112012002130A2 (pt) 2009-08-03 2015-09-15 Aziende Chimique Riunite Angelini Francesco A C R A F S P A processo para a preparação de composto,e, composto intermediário
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
AU2019441740B2 (en) 2019-04-18 2025-12-18 Tracery Ophthalmics Inc. Detection, prediction, and classification for ocular disease
EP3990433B1 (de) 2019-06-25 2026-05-20 Translatum Medicus Inc. Verfahren zur herstellung von 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropansäure und ihren derivaten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1194564B (it) * 1983-04-18 1988-09-22 Acraf Impiego del bendazac e dei suoi sali nel trattamento della retinite pigmentosa
EP0191520B1 (de) * 1985-02-12 1989-06-21 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (1-Phenylmethyl-5-hydroxy-1H-indazol-3-yl)-oxyessigsäure und deren Salze zur Verwendung als Heilmittel und diese enthaltende pharmazeutische Zusammensetzungen
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo

Also Published As

Publication number Publication date
BG61366B2 (bg) 1997-06-30
CA2066304C (en) 2005-06-21
EP0510748B1 (de) 1996-03-20
CS122792A3 (en) 1992-11-18
ITMI911101A0 (it) 1991-04-22
IL101660A (en) 1996-08-04
IT1253703B (it) 1995-08-23
ITMI911101A1 (it) 1992-10-22
JPH0640915A (ja) 1994-02-15
ZA922740B (en) 1992-12-30
DK0510748T3 (da) 1996-07-22
AU657524B2 (en) 1995-03-16
KR920019350A (ko) 1992-11-19
CZ280613B6 (cs) 1996-03-13
AU1488392A (en) 1992-10-29
DE69209128D1 (de) 1996-04-25
KR100210199B1 (ko) 1999-07-15
CA2066304A1 (en) 1992-10-23
SK278546B6 (en) 1997-09-10
JP3056879B2 (ja) 2000-06-26
US5278183A (en) 1994-01-11
DE69209128T2 (de) 1996-11-28
NZ242392A (en) 1997-06-24
EP0510748A1 (de) 1992-10-28

Similar Documents

Publication Publication Date Title
DE69201948D1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
GB9202791D0 (en) Compounds
ATE283047T1 (de) Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose
DE69209128D1 (de) Verwendung von Indazol-Methoxyalkansäure zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunkrankheiten
ATE205712T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der angiogenese und angiogene krankheiten
ES2060173T3 (es) Derivados de lisolecitina para el tratamiento de enfermedades autoinmunologicas.
DE3873578D1 (de) Verwendung von tetrahydrobenz(c,d)indol-6-carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
ATE199642T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung des knorpelabbaus
ATE123944T1 (de) Verwendung von trifluormethylphenyl- tetrahydropyridinen zur herstellung von arzneimitteln zur behandlung anxio-depressiver erkrankungen.
DE3888340D1 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
DE68908145D1 (de) Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien.
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE138573T1 (de) Verwendung von xanthinderivaten zur herstellung eines arzneimittels zur behandlung von sekundären nervenzellschäden und funktionsstörungen nach schädel-hirn-traumen
DE69222570D1 (de) Phosphonsäurederivate, Verfahren zur Herstellung und ihre Verwendung
EP0354568A3 (de) Catechol-Derivate
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
ATE31022T1 (de) Verwendung von 4,5'-azo-bis-salicylsaeure zur herstellung eines arzneimittels zur behandlung entzuendlicher darmkrankheiten.
DE69708084D1 (de) Verwendung von pyridyl- und pyrimidyl-piperazinen zur herstellung eines medikaments zur behandlung von rauschgiftsbedingten beschwerden
DE68910010D1 (de) Verwendung von Dapiprazol zur Herstellung eines Arzneimittels zur Verhinderung des Toleranzentwicklung bei der analgetischen Behandlung mit Morphin.
ATE121623T1 (de) Verwendung von quinazolinen zur herstellung eines arzneimittels zur behandlung und vorbeugung von arrhythmie.
ATE173921T1 (de) Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
NO164170C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-benzhydryl-4-cinnamyl-piperazinderivater.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification